Twitter's board put up a defense mechanism against Elon Musk. Here's what he could do next
CNN
Twitter has indicated that it's not interested in being bought by the world's richest man without a fight. The social network's board made a defensive maneuver that could thwart Elon Musk's takeover bid, but he still has a range of options that suggest this Silicon Valley showdown is likely far from over.
Twitter's board said on Friday it was implementing a shareholder rights plan, known as a "poison pill," that would make it harder and more expensive for Musk (or any other would-be buyer) to acquire the company without the board's approval. The plan came a day after Musk made an offer to acquire all the shares in Twitter (TWTR) he does not own for $54.20 a piece, valuing the company at around $41 billion. That represents a 38% premium over Twitter's closing share price the day before Musk's large ownership stake was revealed.
The poison pill plan, detailed in a filing with the Securities and Exchange Commission on Monday, will remain in place for nearly a year and will be triggered if Musk (or any other investor) expands his stake in the company to 15%; he currently owns around 9% of shares. It would give all other shareholders the right to buy one additional share for each share they own at a discount. While other shareholders executing their rights to buy new stock under the plan would have to pay $210 for each new share they purchased, Musk (or another hostile investor) would have to pay $420. (Twitter's team proved Musk isn't the only one capable of spicing up a serious corporate standoff with marijuana references.)
Run 3 Space | Play Space Running Game
Traffic Jam 3D | Online Racing Game
Duck Hunt | Play Old Classic Game
Falling vaccination rates could lead to the return of previously eliminated diseases, and many more people will be at risk of catching those diseases.
From Madonna to Jack Nicholson, this performance artist attends Paris Fashion Week impersonating some of the world’s most famous celebrities. CNN got a glimpse behind the making of his latest look.
The US Department of Health and Human Services called off an upcoming meeting of expert advisers on preventive health care, raising questions about the future of the longtime nonpolitical advisory group.
An international team of researchers may have just cracked the code for what makes someone “cool.”
After trying to conceive for 18 years, one couple is now pregnant with their first child thanks to the power of artificial intelligence.
Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.
A tender image of love on Chicago’s lakefront, taken by Doug Ischar, was archived for decades. Now, his 1985 series “Marginal Waters” is being resurfaced in a new exhibit at the MCA Chicago.
After recent moves by the US Department of Health and Human Services to restrict the approval and use of some vaccines — and signs that more changes might be coming — some states and private partnerships are scrambling to ensure that vaccines will still be available to those who want them.